- Home
- RZLT vs GNFT Comparison
RZLT vs GNFT Comparison
Compare RZLT & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLT
- GNFT
- Stock Information
- Founded
- RZLT 2010
- GNFT 1999
- Country
- RZLT United States
- GNFT France
- Employees
- RZLT N/A
- GNFT N/A
- Industry
- RZLT Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RZLT Health Care
- GNFT Health Care
- Exchange
- RZLT Nasdaq
- GNFT Nasdaq
- Market Cap
- RZLT 292.0M
- GNFT 296.4M
- IPO Year
- RZLT N/A
- GNFT 2019
- Fundamental
- Price
- RZLT $4.08
- GNFT $3.79
- Analyst Decision
- RZLT Strong Buy
- GNFT Strong Buy
- Analyst Count
- RZLT 8
- GNFT 1
- Target Price
- RZLT $11.63
- GNFT $13.00
- AVG Volume (30 Days)
- RZLT 375.4K
- GNFT 7.5K
- Earning Date
- RZLT 02-11-2025
- GNFT 09-19-2024
- Dividend Yield
- RZLT N/A
- GNFT N/A
- EPS Growth
- RZLT N/A
- GNFT N/A
- EPS
- RZLT N/A
- GNFT 0.47
- Revenue
- RZLT N/A
- GNFT $86,225,222.00
- Revenue This Year
- RZLT N/A
- GNFT $155.44
- Revenue Next Year
- RZLT N/A
- GNFT N/A
- P/E Ratio
- RZLT N/A
- GNFT $7.65
- Revenue Growth
- RZLT N/A
- GNFT 175.45
- 52 Week Low
- RZLT $0.86
- GNFT $3.31
- 52 Week High
- RZLT $6.19
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- RZLT 26.54
- GNFT 30.99
- Support Level
- RZLT $4.42
- GNFT $3.63
- Resistance Level
- RZLT $5.29
- GNFT $3.85
- Average True Range (ATR)
- RZLT 0.37
- GNFT 0.12
- MACD
- RZLT -0.09
- GNFT 0.02
- Stochastic Oscillator
- RZLT 0.68
- GNFT 20.82
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.